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 ABSTRACT 
 
Mutations are responsible for causing various human diseases, including several types 
of cancer and immunodeficiency syndromes. They can either be involved directly in the 
pathogenesis of the disease or by influencing the treatment efficacy and cause failure of 
the patient’s response to a specific therapy by adapting the targeted cell to resist the 
treatment.  
 
In paper I, we generated amino acid substitution variations of BTK at ibrutinib binding 
site C481, and performed functional analysis for the corresponding proteins. We have 
also studied various phosphorylations, which are affected by ibrutinib treatment and put 
our results in a structure-function context. Herein, we demonstrated that substitution of 
cysteine 481 by threonine (C481T) retained the kinase activity and caused ibrutinib 
resistance. So we identified a new escape mutant for irreversible BTK inhibitors, which 
we predict to be found in patients. BTK kinase is completely inactivated by amino acid 
(codon) replacement of C481 with arginine, phenylalanine, tryptophan or tyrosine, 
while the activity is severely impaired when C481 replaced by glycine.  
 
In paper II, we have compared the role of N-terminal region domains in the 
regulation of SYK fusion kinases in terms of phosphorylation, activation, stability and 
localization. Upon translocation, SYK contributes its kinase domain into two known 
fusion-proteins, ITK-SYK and TEL-SYK. We have also generated analogous B-cell 
fusion kinase, BTK-SYK for comparison. The fusion kinases showed differential 
activation, localization and sensitivity to various inhibitors. Here, we report the 
activation-mediated nuclear translocation of ITK-SYK, which is rarely seen among 
kinases. This unique feature of ITK-SYK is therefore of general interest, as its 
potential relation to ITK-SYK’s transforming capability. 
 
In paper III, we have identified a hypomorphic mutation in PGM3 gene replacing 
isoleucine 322 with threonine in a family with immunodeficient children, described 
previously. The mutation is severely destabilized and impaired the enzymatic activity 
of the protein, causing the described phenotype. 
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 LIST OF ABBREVIATIONS !
ALL Acute lymphoblastic leukemia BCR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!B%cell!receptor!
BLNK                          B-cell linker protein !BTK!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Bruton’s Tyrosine Kinase  
CDG                            Congenital disorder of glycosylation  
CLL Chronic lymphocytic leukemia 
DLBCL Diffuse large B-cell lymphoma 
EBV                            Epstein–Barr virus !
FL                              Follicular lymphoma !ITAM!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Immunoreceptor tyrosine based activation motif !
ITK                             IL-2-inducible T-cell kinase  LAT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Linker for activation of T-cells!
MCL                          Mantle cell lymphoma 
NFAT                        Nuclear factor of activated T-cells  
NFκB                         Nuclear facto kappa B !
PGM3                        Phosphoglucomutase-3   
PH                              Pleckstrin homology  
PID                           Primary immunodeficiency   
PI3K                          Phosphatidylinositol-3 kinase 
PLCγ                         Phospholipase Cγ !PTCL!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Peripheral T-cell lymphoma!
SFK                           SRC family kinase !
SH2                           Src homology 2 !
 SH3                           Src homology 3  
SLP-76                      SH2 domain containing leukocyte protein of 76kDa 
SYK                          Spleen tyrosine kinase  TCR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!T%cell!receptor!
TEL                           Translocation-ETS-Leukemia!
TFK                           TEC family kinase!
TH                             Tec homology  
WM                          Waldenström’s macroglobulinemia 
XLA                          X-linked agammaglobulinemia !
Xid                            X-linked immunodeficiency  
ZAP-70                     Zeta-chain associated protein kinase of 70 KDa !
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1 INTRODUCTION 
 
The human body is made up of trillions of cells with specific functions, and a large 
number of proteins are involved to control the proper function of the cells. Genes are 
parts of DNA sequence that regulate the expression and activity of different proteins in 
various cells/tissues (1,2). Sometimes, an alteration in the single amino acid coding 
portion of a gene can disturb the synthesis or function of cellular proteins, which in turn 
will affect on the development and function of the cell and may cause abnormal 
conditions (3,4).  
 
Mutations can alter the sequence of a gene in the DNA. The defect can occur in single 
gene or multiple genes, it can also affect part or entire chromosome (5). Mutations 
divide generally into two major types, somatic mutation and germ line mutation. 
However, there are several methods for the classification of gene mutations, which 
based on how the DNA sequence or structure is changed and how this change affects on 
the function and expression of the corresponding protein. 
 
Mutations play a direct role in the occurrence of variety of human disorders, including 
several types of cancer and immunodeficiency syndromes. However, the mutation 
could be embryonically lethal if the affected gene is important for the development. 
Since the immune system mainly is needed upon birth, immunodeficincies are in 
general not embryonically lethal. Moreover, mutations can also affect on the patient’s 
response to the treatment and induce drug resistance (6,7). Identification of the genetic 
alteration contributes to the understanding the molecular mechanism of the disease and 
facilitates treatment strategies. 
 
1.1 LYMPHOID MALIGNANCIES  
 
Lymphocytes are a subset of white blood cells that circulate in blood and in the 
lymphatic system. They consist of three basic classes, B-cells, T-cells and natural killer 
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cells (8,9). Lymphocytes are important part of immune defense that control and mediate 
various immune responses in both innate and adaptive immunity (10,11). 
 
Wide varieties of hematological malignancies originate from lymphocytes, including 
more than 40 different types of lymphoid leukemias and lymphomas, each with distinct 
behavior, prognosis, and pathological characteristics (12,13). Lymphoid malignancies 
arise from any stages of T and B cells development, and are categorized into five major 
classes according to WHO classification; Hodgkin lymphoma, precursor lymphoid 
neoplasm, mature T-cell and natural killer cell neoplasms, mature B-cell neoplasms and 
immunodeficiency-associated lymphoproliferative disorders.  
 
Like in other malignancies, many types of lymphoid neoplasms have been associated 
with genetic alterations that promote cancer cell development and survival, such as 
activating point mutations or chromosomal translocations, and many of these genetic 
lesions have been identified (14,15). For example, t(7;9)(q34;q34.3) chromosomal 
translocation that constitutively activating NOTCH1 has been detected in 50% of T-
lineage acute lymphoblastic leukemia (T-ALL) (16). The most two common 
translocation events in B-lineage acute lymphoblastic leukemia (B-ALL) are t(12;21) 
(p13;q22) translocation that encodes TEL-AML1 leading to activation of JAK-STAT 
signaling pathway, and BCR-ABL1 translocation event that present in 25% of adult 
ALL (17). Moreover, t(5;9) (q33;q22) chromosomal translocation generating ITK-SYK 
chimeric oncogene  recurrently detected in a subset of peripheral T-cell lymphoma 
(PTCL) (18). 
 
Furthermore, gain-of-function genetic alterations affecting CARD11 and CD79B have 
been detected in diffuse large B-cell lymphoma (DLBCL), in addition to the mutations 
of the adaptor protein MYD88 that recognized in Waldenström’s macroglobulinemia 
(WM) and DLBCL, which support the survival of malignant cells (19,20). Sometime 
these genetic alterations do not cause the disease, rather they induce drug resistance, 
such as C481S variation in Bruton’s Tyrosine Kinase (BTK), that induces ibrutinib 
resistance in a subset of patients with chronic lymphocytic leukemia (CLL) and mantle 
cell lymphoma (MCL) (21).  
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1.2 T-LYMPHOCYTE 
 
T-lymphocytes are essential component of the immune system and play a pivotal role in 
cell-mediated immune responses. They originate in bone marrow from common 
lymphoid progenitors; afterward the immature T-cells migrate into thymus in which 
they undergo several developmental stages characterized by co-receptor expression. 
The double negative CD4−CD8− thymocytes start the maturation and progress to 
become double positive CD4+CD8+ thymocytes that undergo negative and positive 
selection processes and transform into mature single positive CD4+ or CD8+ T-cells 
with αβ-T-cell receptor (TCR) expression (22-25). Thereafter, the naïve T-cells are 
ultimately released in peripheral lymphoid tissues (26).  
 
T-cells are involved in various immunological functions and divided mainly into three 
distinct lineages: 1) helper or (CD4+) T-cells, that facilitate the activity of different 
types of immune responses by releasing different cytokines, 2) cytotoxic or (CD8+) T-
cells, in which they directly destroy virally or bacterially infected cells and cancer cells, 
3) regulatory or (suppressor) T-cells, that are in charge for maintaining self-antigen 
tolerance and protecting against aberrant immune responses and autoimmune diseases 
(11,27,28).  
 
Upon stimulation of TCR by the MHC molecule on the antigen-presenting cells, LCK, 
which is a member of SRC family kinases (SFK), phosphorylates the tyrosine residues 
of CD3 immunoreceptor tyrosine based activation motif (ITAM), followed by 
recruitment and binding of zeta-chain associated protein kinase of 70 KDa (ZAP-70) to 
phosphorylated ITAM. The activated ZAP-70, in turn, induces downstream signaling 
by phosphorylating linker for activation of T-cells (LAT), which promotes the 
aggregation of signaling components involving IL2- inducible T-cell kinase (ITK), 
phosphatidylinositol-3 kinase (PI3K), SH2 domain containing leukocyte protein of 76 
kDa (SLP-76) and phospholipase Cγ1 (PLCγ1), followed by activation of several 
downstream signaling cascades leading to cell proliferation, activation and cytokine 
production (29-33). 
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1.3 B-LYMPHOCYTES 
 
B-cells are one of the major sub-types of lymphocytes that originate from 
hematopoietic stem cells in bone marrow. They are an essential component of immune 
system and one of the key effectors of adaptive immunity (10). They are considered as 
positive regulators of immune responses, specialized in production of antibodies 
providing defense against different pathogens.  Furthermore, B-cells are involved in 
other immunological functions including antigen presentation and cytokine secretion 
(34-36).  
 
In humans, B-cells undergo several developmental stages. The first stage of the 
development that occurs in bone marrow is an antigen independent stage. This stage 
includes the differentiation of progenitor B-cell (pro-B-cells) to precursor B-cells (pre-
B-cells), which further developed into immature B-cells. When the cells leave bone 
marrow and enter into the periphery, they become mature B-cells that co-express IgD 
and IgM molecules, and migrate to the lymphoid organs in which the second stage, 
antigen dependent stage, will start (37). This stage involves activation and further 
differentiation of mature B-cells into memory B-cells or antibody secreting plasma 
cells. B-cells that fail antigen recognition undergo programmed cell death, apoptosis 
(38). 
 
B-cell receptor (BCR) signaling is crucial for B-lymphocytes proliferation, 
differentiation and survival. Functional BCR consists of two identical transmembrane 
immunoglobulin heavy chains (IgH) and two identical covalently associated light 
chains (IgL) paired with heterodimer co-receptor Igα (CD79α) and Igβ (CD79β) 
(39,40). The cytoplasmic tails of CD79 contains ITAM that is required for signal 
transduction (39,41).  
BCR-antigen binding induces the SFKs to phosphorylate the tyrosine residues within 
ITAMs, which followed by formation of signaling complex of multiple protein tyrosine 
kinases and adaptor proteins, involving PI3K, B-cell linker protein (BLNK), spleen 
tyrosine kinase (SYK), BTK and PLCγ2, followed by PKC activation and calcium 
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mobilization, leading to activation of different transcription factors that induce B-cell 
proliferation, differentiation and antibody production (42-47). 
 
 
Figure 1. A simplified model of BCR/TCR signaling. BCR components are depicted in 
blue and TCR components are depicted in orange. 
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1.4 PROTEIN TYROSINE KINASES 
1.4.1 Bruton’s Tyrosine Kinase (BTK) 
 
BTK is a cytoplasmic non-receptor tyrosine kinase, where the first clinical correlation 
has been identified in 1993, belonging to TEC family kinases (TFK) (48). BTK is 
constitutively expressed in most hematopoietic cells including both lymphoid and 
myeloid lineages (except plasma cells and T-cells) (49-51). Expression of BTK starts 
from very early stages of B-cell maturation, and is detected in all stages prior to 
terminally differentiated plasma cell (51-53).  
 
The BTK gene is located on the q arm of the X chromosome in the 21.3-22 region (54-
56). The protein is composed of 659 amino acids with structure similar to other 
members of TEC family kinases, consisting of five structural domains, which are 
essential for the regulation of various function of the protein. Starting with Pleckstrin 
homology (PH) and Tec homology (TH) domains at the N-terminus, that mediate 
plasma membrane binding, followed by Src homology 3 (SH3), for association with 
other proteins, Src homology 2 (SH2), for interaction with phosphorylated tyrosine 
residues, and kinase (SH1) domain in the C-terminus (Figure 2) (57-59). The protein 
has molecular weight of 77 KDa.  
 
BTK plays a pivotal role in the BCR signaling and it is critical for B-cell maturation 
and survival (60,61). Loss-of-functional mutations in BTK gene cause B-cell 
developmental defects, giving rise to a severe B-cell deficiency with lack of antibody 
production, leading to an immunodeficiency syndrome called X-linked 
agammaglobulinemia (XLA) (62). The disease was first described in 1952 by Ogden C. 
Bruton. Most of the affected patients are diagnosed in early childhood, and 
characterized by recurrent, severe bacterial infections, mostly respiratory tract and 
gastrointestinal infections, due to absence of serum immunoglobulins of all classes (63). 
A milder phenotype, X-linked immunodeficiency (Xid), was observed in mice, and 
caused by substitution of arginine 28 with cysteine in the PH domain of BTK (64,65). 
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Two signaling steps are required for complete BTK activation, PH domain mediated 
membrane localization, and SFK mediated trans-phosphorylation (66,67). Following 
BCR stimulation, the tyrosine residues of the CD79 ITAM are phosphorylated by the 
activated SFKs, LYN and FYN (42,68,69). These subsequently serve as docking sites 
for the SYK kinase. Concomitantly, PI3K also becomes activated and generates the cell 
membrane-bound phosphatidylinositol 3,4,5- trisphosphate (PIP3), leading to PH 
domain mediated membrane translocation of BTK (70,71). The membrane-localized 
BTK is trans-phosphorylated by SFKs at tyrosine 551 in the catalytic region, which 
induces the auto-phosphorylation of tyrosine 223 residue in the SH3 domain. Activated 
BTK phosphorylates its direct substrate, PLCγ2 at Y753 and Y759, which hydrolyzes 
PIP2 into IP3 and DAG (44,67). This will lead to Ca+2 mobilization and PKC 
activation, followed by induction of several transcription factors necessary for 
proliferation, maturation and survival of B-cell (72,73). 
 
BCR signaling is likely the key driver that promotes progression of B-cell leukemias 
and lymphomas (74,75). Although, constitutively active mutants of BTK have not been 
reported in patients with B-cell malignancies, studies have shown the involvement of 
BTK dependent pathways in the pathogenesis of various B-cell malignancies (76,77).  
 
Moreover, BTK also has a functional role in signaling of chemokine receptor pathways 
that involve in tumor cell migration and homing, such as CXCR4, CXCR5 (78-80). 
This explains the redistribution of malignant cells from the lymphoid tissue into the 
peripheral blood following treatment of patients with BTK inhibitor. In addition, BTK 
is involved in chemokines CCL3, CCL4 secretions by malignant cells, and regulates 
integrin-mediated interaction of tumor cells with the microenvironment (81,82).  
 
The involvement and central role of BTK in pro-survival pathways and 
microenvironment survival signals of tumor cells provide a general rationale for 
developing small molecule inhibitors targeting BTK (83). 
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1.4.1.1 FIRST GENERATION BTK INHIBITOR  
1.4.1.1.1 Ibrutinib 
 
In 2007, Pan and co-workers at Pharmacyclics synthesized a series of small molecule 
inhibitors of BTK. Because of the high efficacy and specificity for inhibiting BTK in 
preclinical models, the compound known as PCI-32765 or ibrutinib, was selected 
among the different compounds for further clinical trials (84). This compound showed 
encouraging clinical activities in various B-cell lymphomas and soon became the first 
US Food and Drug Administration (FDA) approved BTK inhibitor for the treatment of 
several lymphoproliferative malignancies (85-87). 
 
Ibrutinib (imbruvica) is a first-in-class, orally administered, potent, selective, 
irreversible inhibitor of BTK with half maximal inhibitory concentration (IC50) of about 
0.5 nM/L (84,88). The drug abrogates the enzymatic activity of BTK by forming an 
irreversible covalent bond with cysteine-481 in the ATP binding site, thereby blocking 
BCR signal transduction (89-91). Ibrutinib has demonstrated impressive clinical 
efficacy in a variety of B-cell malignancies, and is now approved in the United States 
and in Europe for the treatment of CLL, MCL and WM (92-95). Moreover, the drug 
also shows promising and encouraging preclinical results against inflammatory and 
autoimmune diseases (85,96). 
 
Ibrutinib is rapidly absorbed and eliminated after oral administration, reaching 
maximum serum concentration in 1-2 hours (92). The drug has short half-life (2-3 h), 
but because of its covalent binding to BTK, it can be given once daily, with BTK 
active-site occupancy at the dose of 420 mg, which remains covalently bound to BTK 
for 24 h (92,97). 
 
Ibrutinib is generally well tolerated, and usually associated with grade 1-2 side effects, 
such as diarrhea, nausea, dyspnea, bleeding, fatigue and infections, that are self-limited 
and not required therapeutic intervention (98,99). Grade 3-4 toxic effects also reported 
in small population of patients, including, anemia, neutropenia and thrombocytopenia 
(99). These side effects could result from off-target effects of ibrutinib, since the drug 
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could also bind and inhibit other tyrosine kinases that have similar cysteine residue in 
the ATP binding site, including TEC, ITK, TXK, BMX, HER2, HER4, EGFR, BLK 
and JAK3 (91,100,101).  
 
Additionally, the drug also affects other proteins that do not contain the cysteine 
residue, such as HCK, LCK, BRK, CSK and FRG, which might also contribute to the 
efficacy or toxicity of ibrutinib (85,101).  
 
1.4.1.1.2 RESISTANCE MECHANISMS FOR IBRUTINIB 
 
The ability of the malignant cells to adapt and develop resistance against targeted 
therapies is the main problem that limits the effectiveness of the treatment. Despite the 
clinical effectiveness of ibrutinib in multiple B-cell malignancies, not all the patients are 
responding to the drug, and small subset of patients treated with the drug have 
developed resistance (Figure 3) (102). 
 
Mutation is the most potential mechanism of primary or acquired resistance to ibrutinib. 
These mutations mostly affect BTK or its direct downstream substrate PLCγ2 (103). 
The replacement of cysteine 481 with serine residue in BTK is the most common 
mutation that has been identified in the resistant patients with CLL or MCL 
(21,104,105). This will disrupt the covalent binding of ibrutinib, converting the 
irreversible inhibition of BTK to reversible inhibition, and decrease ibrutinib’s affinity 
for BTK (106).  
 
In addition to the BTK C481S mutation, a variety of acquired activating mutations in 
PLCγ2 have also been detected in mutation-prone patients with CLL. These gain-of-
function mutations of PLCγ2 will bypass BTK entirely and induce activation of BCR 
downstream signaling that is not inhibited by ibrutinib (107,108).  
Moreover, other BTK mutations like (C481F, C481R, C481Y, T474S, T474I and 
L528W) that are associated with BTK C481S or PLCγ2 variations have also been 
implicated in rare cases (107,109). 
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Recently, a study has reported the identification of a novel mutation (T316A) in the 
SH2 domain of BTK in ibrutinib resistant CLL patient, which is the first reported BTK 
mutation outside the kinase domain. However, how this mutation alters the drug 
binding is not well understood (110). 
Interestingly, ibrutinib-resistant patients with DLBCL were associated with mutations 
that activated MYD88 or CARD11, whereas CXCR4 mutations confer resistance to 
ibrutinib in WM (111-113). 
 
1.4.1.2 SECOND GENERATION BTK INHIBITORS 
1.4.1.2.1 Acalabrutinib 
 
Due to the off-target unwanted effects as well as development of resistance to ibrutinib, 
second-generation BTK inhibitors with enhanced selectivity and retained efficacy 
against mutated BTK have been developed (114,115).  
 
Acalabrutinib (ACP-196) is a new selective, highly potent, more specific, and 
irreversible second-generation BTK inhibitor, which also binds covalently to cysteine-
481 in the kinase region (115,116). The drug was designed to have improved target 
specificity and efficacy compared to ibrutinib (117). Only one case of acalabrutinib 
resistance has been observed so far, the patient had BTK C481S and PLCγ2 L845F 
resistant mutants (115). Also other BTK inhibitors such as CC-292, ONO/GS-4059 and 
BGB-3111 are being evaluated clinically for the treatment of hematologic malignancies 
(48,118).  
 
1.4.2 IL-2-inducible T-cell kinase (ITK) 
 
ITK, also known as EMT (expressed in mast cells and T lymphocytes), is a member of 
TFKs that expressed predominantly in T-lymphocytes along with Natural Killer cells 
and Mast cells (119,120).  The kinase plays a major role in T-cell receptor signaling and 
it is crucial for the T-lymphocyte development, activation and survival (121-123). Loss-
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of-function mutations of ITK cause severe, frequently fatal Epstein–Barr virus (EBV) 
infections (124). 
 
Similar to other TFKs, ITK structure contains a C-terminal kinase domain, preceded by 
SH2, SH3 and TH domains, in addition to the N-terminal PH domain (Figure 2) 
(58,125). Upon T-cell receptor stimulation, ITK is translocate to the cell membrane via 
its PH domain, and subsequently trans-phosphorylated on its kinase domain tyrosine 
511 residue by SFK, LCK. ITK then induces tyrosine phosphorylation of its 
downstream substrate, PLCγ1. Activated PLCγ1 hydrolyzes PIP2 into the second 
messengers IP3 and DAG, that induce Ca+2 mobilization thereby activation of nuclear 
factor of activated T-cells (NFAT) and nuclear factor kappa B (NFκB) transcription 
factors (29,126,127). 
 
Many inflammatory and autoimmune diseases are mediated by aberrant activation of T-
cells, and as a key molecule in TCR signaling, ITK became an attractive therapeutic 
target in these diseases. Preclinical in vivo studies have been started using ITK 
inhibitors for the treatment of allergic asthma and other inflammatory diseases (128-
130). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of ITK and BTK domain structures, showing the 
regulatory phosphorylation sites. 
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Figure 3. A model illustrating different ibrutinib resistance mechanisms in B-cell 
malignancies. 
 
1.4.3 Spleen tyrosine kinase (SYK) 
 
The non-receptor tyrosine kinase SYK together with its homologous, ZAP-70 are the 
only two members of the SYK/ZAP-70 family kinase (131). SYK showed a wide 
distribution pattern, the kinase is highly expressed by lymphocytes and myeloid cells. It 
is also expressed by non-hematopoietic cells, such as hepatocytes, neuronal cells, 
osteoclasts and epithelial cells (131-133). SYK deficient mice die prenatally due to an 
extensive hemorrhage caused by a defect in vascular tissue (134). 
 
SYK possesses two N-terminal SH2 domains for association with other proteins, that 
are connected by inter domain A, and they separated from C-terminal catalytic region 
by inter domain B (Figure 4) (135,136). 
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SYK is crucial for signal transduction in different cell types and has diverse roles in 
immune and non-immune biological events. The kinase is essential for signaling via 
classical immunoreceptors (BCR, TCR and Fc receptor (FcR)), and induces further 
downstream signaling events leading to cytokine production, antibody production, cell 
proliferation, differentiation and survival (137,138). Moreover, it has been implicated in 
antifungal immunity through CLEC-7A-SYK-CARD9 pathway activation and IL#1β 
production in response to fungal infection (139,140). 
 
Furthermore, SYK has been found to be a key molecule in several non-immune 
responses; including bone metabolism, which is required for osteoclast development 
and function. SYK-dependent signaling pathways are also important for platelet 
function as well as vascular development and integrity (141).  
 
In resting cells, SYK retains a closed, auto-inhibitory conformation (142). Upon 
immunoreceptor engagement, SFK phosphorylate ITAM tyrosine residues; this follows 
by translocation of SYK to plasma membrane through binding of its N-terminal SH2 
domains to the phosphorylated ITAM (143). Binding to ITAM abolishes the auto-
inhibitory state and induces SYK phosphorylation at key tyrosines in the linker-region 
(Y352) and activation loop (Y525/526), which are crucial for kinase activation 
(144,145). SYK mediated signal transduction cascades recruit several kinases and 
adaptor proteins that initiate downstream responses, such as VAV, BLNK, PI3K and 
PLCγ2 (146,147). SYK activity is tightly controlled, and several regulatory molecules 
are involved in the negative regulation of SYK, such as protein tyrosine phosphatases 
SHP1 and PTPROt, and the E3 ubiquitin ligase CBL, which regulates SYK 
expression (148-150). 
 
An alternatively spliced shorter variant of SYK (SYK-B) has been detected in mouse, 
rat and human cells. The two isoforms share the major structural domains, but SYK-B 
lacks 23 amino acid insert in the inter domain B, including nuclear localization signals 
(151). Therefore, they show differential subcellular localization. Unlike full length SYK 
that localizes both in the nucleus and cytoplasm, the shorter isoform is predominantly 
cytoplasmic (152,153).  
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SYK may function as an oncogene and contributes in growth and survival of various 
hematological malignancies, since over expression or deregulated SYK activity has 
been observed in different B-cell and T-cell neoplasms, such as CLL, MCL, DLBCL, 
follicular lymphoma (FL) and PTCL (154-157). Moreover, involvement of SYK in 
two different chromosomal translocation events, leads to expression of enzymatically 
active fusion kinases, ITK-SYK, in PTCL and TEL-SYK, in myelodysplastic 
syndrome, further supporting the possible oncogenic role of SYK in hematological 
malignancies (18,158). 
 
 
Notably, SYK has been reported as tumor suppressor in multiple non-hematopoietic 
cancer types. Several clinical studies have shown that the down-regulation of SYK in 
breast cancer, gastric cancer and melanoma correlates with poor prognosis of the 
disease (159). However, this relationship remains elusive.  
 
Given the involvement of SYK in various signaling pathways in multiple immune and 
non-immune biological responses, and its role in the pathogenesis of malignant and 
inflammatory disorders, the kinase became a promising therapeutic target in those 
diseases (160). Fostamatinib, the orally administered SYK inhibitor that targets the 
conserved ATP binding site has shown potential therapeutic efficacy in the treatment 
of autoimmune diseases, and CLL (161,162). 
 
1.5 SYK FUSION KINASES 
1.5.1 ITK-SYK 
 
PTCL are heterogeneous, highly aggressive non-Hodgkin’s lymphomas with a high 
mortality rate arising from mature T-cells and infiltrating different organs such as 
lymph nodes, spleen, liver and skin. Among PTCLs, unspecified peripheral T-cell 
lymphoma (PTCLU) represents the most common subtype (163). Recurrent 
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chromosomal translocation and generation of active fusion proteins were found to be 
important driver of various malignancies. Novel t(5;9)(q33;q22) translocation was first 
described in 2006 as a recurrent genomic alteration in 17% of patients with PTCLU 
(18). This gene rearrangement involves ITK and SYK genes on the chromosomes 5 and 
9 respectively. Consequently, the first 165 amino acids from the N-terminal PH and TH 
regions of ITK coupled with the 330 amino acids from C-terminal inter domain B and 
kinase domain of SYK, yielding a chimeric oncogene ITK-SYK (495 amino acids) 
(Figure 4), which is believed to be the cause of the disease (164,165). 
 
 Biochemical and functional studies have shown that ITK-SYK is a constitutively active 
tyrosine kinase, which phosphorylates various downstream signaling proteins like SLP-
76, PLCγ1, AKT and ERK, and induces CD69 up-regulation and IL-2 production in T-
cells (166-168). In vivo expression of the fusion kinase induces T-cell transformation 
and yielding aggressive T-cell lymphoma with phenotype similar to human disease 
(169). The transforming capacity of ITK-SYK is kinase dependent. 
 
In mice, T-cell specific expression of ITK-SYK causes T-cell lymphoproliferation with 
systemic inflammation (169). The onset of the disease is dependent on the expression 
level of the oncogene. The low expression of ITK-SYK leads to the development of 
aggressive disease within few weeks, while high expression of the fusion kinase will 
cause delayed disease development (20-27 weeks), since the high expression of the 
fusion kinase activates Blimp-1 dependent terminal differentiation of the T-cells (170). 
Surprisingly, B-cell specific expression of ITK-SYK did not induce B-cell malignancy, 
but led to delayed T-cell lymphoma. 
 
Moreover, in vivo studies have shown that SYK inhibitor R406 could potently inhibit 
ITK-SYK-induced T-cell lymphoproliferative disease in mice, which suggests that 
ITK-SYK could be a suitable therapeutic target for the treatment of the patients 
carrying the fusion protein (169).  
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ITK-SYK localizes into different compartments of the cell. Some studies demonstrated 
that ITK-SYK localizes in the plasma membrane, and the membrane localization of the 
kinase is crucial for its transforming potential (167). Interestingly, cytoplasmic 
localized ITK-SYK R29C variant that compromises membrane recruitment, induces 
more aggressive T-cell lymphoma in the transplanted mice (171).  
 
SYK contains a number of regulatory tyrosines in the inter domains A, B and kinase 
domain. ITK-SYK retains most of these tyrosine sites, and it is constitutively 
phosphorylated on both activation loop and linker region tyrosine sites that are required 
for SYK catalytic activity (172). However, there are conflicting results about the role of 
these tyrosine sites in the activity and regulation of ITK-SYK, since it has been shown 
that ITK-SYK is lacking the auto-inhibitory conformation and the open conformation 
structure of the fusion kinase is responsible for the constitutive kinase activity (172). 
 
1.5.2 TEL-SYK 
 
 
ETV6, also known as TEL (Translocation-ETS-Leukemia), is a transcriptional 
repressor belonging to the erythroblast transformation specific (ETS) family, and 
expresses in a wide variety of cells (173). Chromosomal translocations involving TEL 
have been identified in different hematological malignancies, leading to fusion of TEL 
with different protein kinases, such as TEL-JAK2, TEL-TRKC, TEL-ARG, TEL-ABL 
TEL-PDGFβR and TEL-SYK (173-177).  
 
The t(9;12)(q22;p12) translocation yielding TEL-SYK fusion kinase was reported in a 
patient with myelodysplastic syndrome that progressed later to AML (158). The TEL 
part of TEL-SYK fusion contains the N-terminal pointed (PNT) domain linked to C-
terminal linker region and complete kinase domain of SYK (Figure 4) (178). TEL-SYK 
acquires constitutive activation through PNT domain-mediated oligomerization and 
subsequent auto-phosphorylation (179). TEL-SYK induces IL-3 independent growth 
and proliferation of BAF3 cells, causing activation of PI3K, MAPK and constitutive 
tyrosine phosphorylation of STAT5 (179). In vivo, overexpression of the fusion kinase 
in murine pre-B-cells leads to lymphoid leukemia in mice (178,180). 
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Figure 4. Schematic representation of SYK, ITK-SYK and TEL-SYK domain 
structure, showing the corresponding tyrosine sites. 
 
 
1.6 PRIMARY IMMUNODEFICIENCIES (PIDs) 
 
PIDs comprise a heterogeneous group of genetically inherited disorder, which are 
characterized by defective immune responses. These diseases can be inherited in 
different patterns, most commonly by autosomal recessive or X-linked pattern of 
inheritance (181). The defective genes encode destabilized or activity-reduced 
important proteins affecting the function of immune system (182,183).  
 
Generally, the clinical symptoms of these diseases include severe recurrent infections, 
auto-inflammatory disorders and allergy (184). Furthermore, hematologic and non-
hematologic malignancies were often reported with increased frequency as a 
complication of many PIDs (185).  
 
There are over 200 different disorders and more than 200 genetic mutations that have 
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been identified in patients with PIDs (183,186). The severe diseases have an overall 
prevalence of approximately 1:10000 individuals, and they are categorized by IUIS into 
9 general categories depending on the nature of immune defect, including defects in 
innate immunity, predominantly antibody deficiencies, diseases of immune 
dysregulation, auto-inflammatory disorders, combined immunodeficiencies, combined 
immunodeficiencies with associated or syndromic features, congenital defects of 
phagocyte number, function, or both, complement deficiencies and phenocopies of PID 
(187,188). 
 
1.7 Phosphoglucomutase-3  (PGM3)  
 
Glycosylation is a posttranslational modification in which the proteins are modified by 
attachment of sugar moieties to specific amino acid residues. The process is critical for 
the proper folding of the protein, which affects its function and stability. The main two 
types of the glycosylation are N-glycosylation, by which the sugar molecule is attached 
to the amino group of the asparagine side chain, and O-glycosylation, by which the 
carbohydrate is attached to the hydroxyl group of serine or threonine (182,189,190).  
 
Glycosylation has a key role in various biological processes, including cell adhesion, 
migration and immune responses. Defect in glycosylation will lead to an immune 
disease, which associate with skeletal and neurological abnormalities called congenital 
disorder of glycosylation (CDG). Moreover, glycosylation defects have also been 
described to cause PIDs (191,192).  
 
PGM3 or N-acetyl glucosamine-phosphate mutase (AGM1) is an enzyme belonging to 
the hexose-phosphate mutase family that catalyzes the conversion of N-acetyl-
glucosamine-6-phosphate to N-acetyl-glucosamine-1-phosphate, an important step in 
the hexosamine biosynthesis pathway for the generation of uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc). The latter is an essential component for protein 
glycosylation (193,194).  
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PGM3 is widely expressed in cells of different organs such as bone marrow, liver, 
pancreas and testis. Autosomal recessive mutations affecting PGM3 gene have been 
reported in 23 immunodeficient patients leading to impairment of the protein expression 
and enzymatic function, resulting in the disruption of the glycosylation  (Figure 5)(195-
198). 
 
Patients with hypomorphic PGM3 mutations display similar clinical features, including 
recurrent bacterial, viral and fungal infections associated with allergy and atopic 
disease, in addition to connective tissue and neurologic abnormalities and marked 
elevation of serum IgE level in the majority of the patients (199,200). Moreover, it has 
been reported that complete loss of PGM3 in mice is embryonically lethal (193).  
 
 
Figure 5. Domain structure of PGM3 showing the detected mutation sites. 
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2 AIMS 
 
The objectives of this study are: 
! To characterize the abnormalities in TEC family kinases. 
! To characterize various mutations of BTK at C481 that can cause ibrutinib resistance. 
! To characterize the ITK-SYK fusion protein using biochemical and molecular cell 
biology methods. 
! To compare ITK-SYK activation to that of the TEL-SYK fusion protein. 
! To study the mutations in the PGM3 gene which cause primary immunodeficiency. 
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3 MATERIALS AND METHODS 
 
3.1 CELL CULTURING 
3.1.1 Cell lines 
Jurkat (human T-cell leukemia cell line) BAF3 (Bone marrow-derived IL-3-dependent 
pro-B), DT40 (chicken lymphoma cells), NIH3T3 (mouse embryonic fibroblast), SYF 
(mouse cells deficient in Src, Yes and Fyn), HEK-293T (human embryonic kidney cells) 
and COS-7 (African green monkey fibroblast-like kidney) cell lines were purchased from 
the American Type Culture Collection (ATCC). The B7.10 cell line was donated by Dr. 
T. Kurosaki’s laboratory, Japan.  
 
3.1.2 Primary cells 
Peripheral blood from the patient and healthy controls were collected in EDTA tubes. 
The B-cells from collected samples were subsequently transformed with EBV, then they 
expanded and cultured in RPMI 1640 containing 50 mg/ml Gentamicin with 20% bovine 
serum. 
 
3.2 TRANSFECTION AND ELECTROPORATION  
In this work, two different protocols have been used for transient transfection of the 
plasmids. Polyethylenimine (PEI) has been used for the transfection of the adherent cells. 
All other hematopoietic cells were transfected by using the Neon transfection system, 
using different setting for each cell line according to the manufacture’s protocol. 
 
3.3 PROTEIN ANALYSIS           
3.3.1 Western blot 
Western blot or immunoblot is an important and widely used technique that allows the 
separation and detection of proteins in naïve or phosphorylated states. The fresh made 
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RIPA buffer containing protease and phosphatase inhibitors have been used to facilitate 
cell lysis. Then proteins in the lysate were separated depending on their size by gel 
electrophoresis and subsequently transferred from the gel onto nitrocellulose membranes, 
followed by incubation with proper primary and secondary antibodies. The membranes 
were scanned using Odyssey Imager from LI-COR Biosciences GmbH. 
 
3.3.2 Immunoprecipitation 
Immunoprecipitation is one of the most frequently used methods to isolate and purify a 
particular protein out of the heterogeneous mixture of different proteins, by incubating 
the specific antibody that binds to the targeted protein within the protein mixture. Then 
the antibody-protein complex is pulled down by using protein A or G beads, which 
enable the isolation of desired protein from the rest of the mixture. Western blot or other 
assay techniques can be used for the detection of the precipitated protein. The technique 
is also used to detect protein-protein interactions.  
 
3.3.3 Immunofluorescence microscopy  
Immunofluorescence is a common laboratory technique used to analyze the expression 
and distribution of the interested protein or other molecules within the cell or tissue 
section by using a specific fluorescently labeled antibodies. 
 
The transfected cells were fixed, permeabilized and stained using two antibodies, the 
primary unlabeled antibody that form an immune complex with the targeted protein, and 
fluorophore-conjugated secondary antibody that directed against the primary antibody. 
Images were captured using Olympus microscope (Olympus-IX81), and the images were 
processed using Cell Sense Dimension software (Olympus, Tokyo, Japan). 
 
  3.4   IN VITRO KINASE ASSAY  
In vitro kinase assay is a specific technique in which the enzymatic activity of a kinase 
is measured in purified form without cell lysates. In this method the kinase is incubated 
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with the targeted substrate in the presence of ATP in the kinase reaction buffer, in 
which the kinase will transfer the phosphate group from ATP onto the substrate. In 
our study, the immunoprecipitated BTK, or the BTK mutants, were mixed with 
immunoprecipitated PLCγ2, and the mixture is incubated in the kinase buffer in the 
presence of ATP for 30 minutes at 30 °C.  
 
 3.5 HEALING ASSAY 
The wound-healing assay has been used to study the effect of expression of genes or the 
addition of chemical compounds on the proliferation and migration rates of cells in 
vitro. We used µ-Dish 35 mm, high, with culture insert from ibidi for wound healing 
assay. Cells were transfected with the plasmids, then after 24 hours a suspension of the 
transfected cells were placed in both wells of the silicon-insert, and incubated for 
additional 24 hours at 37 °C and 5% CO2. Then the silicon-insert was removed by using 
sterile tweezers, and a cell free gap of 500 µm was created, and cell images were 
captured at regular intervals using 4X dry objective under fluorescence microscope. 
 
 3.6 NUCLEAR AND CYTOPLASMIC FRACTIONATION 
Nuclear and cytoplasmic fractionation is a commonly used method for the isolation of 
cytoplasmic and nuclear fractions in order to determine the localization of the proteins 
within the cell. We have studied the subcellular localization of SYK fusion kinases in 
the Jurkat cells by using NE-PER nuclear and cytoplasmic extraction reagent kit 
(Thermo Scientific). 
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4 RESULTS AND DISCUSSIONS 
 
4.1 PAPER I 
Substitution scanning identifies a novel, catalytically active 
ibrutinib-resistant BTK cysteine 481 to threonine (C481T) 
variant  
 
Minorities of patients treated with ibrutinib have developed resistance to the drug. 
Resistance to ibrutinib often involves mutation of the cysteine 481 residue in the BTK 
catalytic domain, where ibrutinib binding occurs.  
 
In this study, we generated various variants of BTK mutated at cysteine 481 site and we 
have studied the activity and ibrutinib sensitivity of the generated mutants. Six different 
BTK mutants were generated by replacing cysteine 481 with (phenylalanine, 
tryptophan, arginine, glycine, tyrosine, serine), following single nucleotide substitutions 
of the codon. We have also generated cysteine 481 to threonine replacement, which 
required exchange of two nucleotides. 
 
According to the functional assays, the kinase activity of BTK is completely lost when 
C481 is substituted by phenylalanine, tyrosine, tryptophan or arginine due to the big 
and bulky structures of these amino acids, which cause structural clashes within the 
kinase domain. Substitution with glycine that lacks the polar side chain, which is 
important for functional interaction within kinase domain, severely impaired the kinase 
activity.  
 
Substitutions of cysteine 481 by serine or threonine were the only replacements with 
retained kinase activity. Furthermore, since these variants cannot covalently bind to 
ibrutinib, both would likely be of clinical importance in the development of drug 
resistance. We therefore predict that not only serine, but also threonine escape mutants, 
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not reported to date, could occur in patients treated with BTK inhibitors binding 
covalently to cysteine 481. However, resistance due to threonine substitution is 
expected less frequently as compared to serine, since replacement with threonine would 
require exchange of two nucleotides. 
 
 
Figure 6. Schematic view of BCR signaling pathway illustrating the ibrutinib 
sensitivity of BTK C481 mutants and their effect on downstream signaling (201).  
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4.2 PAPER II 
Differential regulatory effects of N-terminal region in SYK-
fusion kinases reveal unique activation-inducible nuclear 
translocation of ITK-SYK 
 
In this study, we have compared the role of N-terminal region domains for the 
regulation of SYK fusion kinases in terms of phosphorylation, activation, stability and 
localization. We also investigated the effect of these rearrangements on the degree of 
modularity of the domain by studying the functional activity of PH-TH domain in ITK-
SYK and BTK-SYK and PNT domain in TEL-SYK.  
 
We have compared the proliferation and the migration rate, which reflect the oncogenic 
potential of these fusion kinases, by using a wound-healing assay. The healing process 
and the wound gap filling were significantly stronger upon TEL-SYK expression 
compared to ITK-SYK and BTK-SYK expression. We also compared the subcellular 
localization of the fusion kinases and found that BTK-SYK and TEL-SYK are localized 
predominantly in perinuclear region and cytoplasm respectively. Interestingly, ITK-
SYK showed robust activation-mediated nuclear translocation in COS-7 and Jurkat 
cells, using two different methods, western blotting and fluorescence microscopy. 
 
Subsequently, we investigated the activity of the loss of function PH-domain mutant 
ITK-SYK-R29C and BTK-SYK-R28C. Both mutants had retained kinase activity and 
they potently phosphorylated their substrate, SLP-76. In summary, we found that the 
SYK fusion kinases are constitutively active and behave differently from each other, 
although they shared the same kinase domain of SYK, seemingly reflecting the 
differences of the N- terminal region. 
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4.3 PAPER III 
Susceptibility to infections, without concomitant hyper-IgE, 
reported in 1976, is caused by hypomorphic mutation in the 
phosphoglucomutase 3 (PGM3) gene  
 
In this study, we have described a new homozygous mutation in the PGM3 gene 
replacing isoleucine 322 with threonine, in a family with immunodeficient sibling. 
Patients with the identified PGM3 mutation displayed recurrent airway infections, 
varicella, pneumonia and allergy.  
 
The laboratory analysis showed that the patient carrying PGM3 mutation had elevated 
level of eosinophil with reduced neutrophil and lymphocyte counts. The patient had 
increased serum IgA and normal IgE level. 
 
We have also studied the stability of the mutated protein and we found that the EBV 
transformed patient B-cells grew much slower comparing to the control cells. 
Moreover, the immunoblotting result showed that the I322T mutated PGM3 is instable 
and the mutation induces protein degradation. Then we performed functional analysis 
for the protein, and we found that this substitution effectively reduced PGM3 enzymatic 
capacity.  
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5 CONCLUSIONS 
 
These studies have shown that: 
 
Paper I: 
• BTK with threonine substitution at cysteine 481 maintained catalytic activity. 
• Since the C481T variant cannot covalently bind to ibrutinib, it would likely be 
of clinical importance for the development of drug resistance. 
• Resistance due to threonine substitution is expected less frequently as compared 
to serine, since replacement with threonine would require exchange of two 
nucleotides. 
• C481Y, C481F, C481W and C481R variants of BTK are catalytically inactive 
and they predicted to be very scarce and they require compensatory mutations. 
 
Paper II: 
• SYK fusion kinases are constitutively active and behave differently from each 
other. 
• Activation of SYK fusion kinases is not only dependent on the presence of 
intact PH-TH or PNT domains, but also on the absence of an auto inhibitory 
conformation. 
• ITK-SYK robustly translocates to the nucleus upon activation. 
  
Paper III: 
• I322T substitution mutation in PGM3 is a cause of immunodeficiency disease. 
• The mutated protein is severely destabilized and impaired the enzymatic 
activity. 
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